Lingke Pharmaceutical (Hangzhou) Co., Ltd.
 浙ICP备19010130号      Powered by www.300.cn 

CENTER OF DRUG DISCOVERY

Founded on May 8, 2020
By the Institute of Cancer & Basic Medicine,
   Chinese Academy of Sciences and Lynk
   Pharmaceuticals

OUT-LICENSING PARTNER

(To be disclosed later)

IN-LICENSING PARTNERS
Lynk successfully in-licensed RAS
inhibitors with novel mechanism of action
(global rights)from a Kobe university
(Japan) & RIKEN researchinstitute (Japan)
on July 16th, 2020